Tumors of the microsatellite mutator phenotype (MMP) accumulate hundreds of thousands of somatic clonal mutations, preferentially in simple repeats or microsatellites (Ionov et al., 1993) . Among this multitude of irrelevant mutations in 'junk' DNA, quite a few also hit genomic coding regions with potential impact on phenotype. The issue is then how to sort out cause from consequence and mutations that contribute from mutations that are inconsequential to tumorigenesis.
In this issue of Oncogene, Woerner and colleagues make a good effort in this direction, based on a metaanalysis of the mutations in genes with simple repeats reported so far in the literature. The list is extensive and includes more than 100 genes in colon cancer, and near 50 in gastric and endometrial cancers, which are the three human cancers with the highest incidence of microsatellite instability (MSI). The work is based on more than 60 publications during the past few years, which is a good barometer for the interest in this area.
The study is intended to distinguish, among this glut of mutated genes, those whose mutations during tumor progression are under positive selection (i.e. relevant, functional mutations) and those that are not (i.e irrelevant, neutral mutations). The statistical approach is based on stratification of mutation frequency. Some genes showing high mutation frequency are thus categorized as 'common targets' for the MMP in colon, gastric and endometrial cancer. The list includes some familiar names, such as TGFbRII and BAX, and other newcomers. The effort is laudable, in the same line as previous reports by Duval, Iacopetta, Hamelin and colleagues (Duval et al 2002a; Duval and Hamelin, 2002 ) that attempt to find objective criteria for determining mutation functionality.
The topic needs to be put into the right context. The first thought to come to the mind of a hypothetical unprejudiced reader could be to question the necessity to discern the functionality or neutrality of many novel mutated cancer genes in the genesis of tumors with MSI. For instance, colon cancer is well known to involve the mutational activation and inactivation of the prototypical cancer genes K-ras oncogene, and APC and p53 tumor suppressors (Kinzler and Vogelstein, 1995) . Then, why colon cancers with MSI would need additional mutated cancer genes? Would it not be more logical to conclude that mutations in microsatellite sequences, regardless for their coding or noncoding location, are all inconsequential for tumorigenesis in colon tumors with DNA mismatch repair (MMR) deficiency? If they have already become tumors in the first place, they might have done so because of the obligatory APC, K-ras and p53 oncogenic mutations (Kinzler and Vogelstein, 1995) . Would it not be therefore a non-productive and distractive task to scrutinize the 100 plus novel target cancer genes in these tumors?
The answer to such questions is 'certainly not'. This is because of the paradoxically low incidence of mutations in APC, K-ras and p53 in colon tumors of the MMP (Ionov et al., 1993; Kim et al., 1994; Konishi et al., 1996; Perucho, 1999) , the very same tumors that may cram millions of somatic mutations in other DNA sequences. Indeed, a first level of explanation for this paradox is precisely the existence of these MSI-specific cancer genes. Genes never observed mutated in tumors before are now netted in the handful in MSI-positive tumors, because these tumors exhibit a more than two orders of magnitude increase in slippage errors in simple repeats. The first such target gene described was TGFbRII (Markowitz et al., 1995) , which has been found to be mutated in a vast majority of gastrointestinal tumors with MSI. It is no surprise that it is classified in the 'functional' common target category by Woerner et al. (in press) statistical approach.
However, it is difficult to distinguish between relevant and irrelevant mutations in MSI-positive tumors, and the statistical approach of Woerner et al. is not seamless, as they acknowledge. While meta-analyses are intended to erase spurious fluctuations of single observations, some genes included in the study have been analysed only by one group. This leads to true incidence uncertainty. As the procedure relies on the localization of the data points inside or outside an inconclusive bracket zone, slight fluctuation in mutation frequency transmutes the status of some target genes from functional to non-committal and vice versa. For instance, one of the newly identified common target genes is HT001, for which there is no evidence of involvement in neoplasia. The gene exhibits the highest mutation incidence (17 mutations in 20 tumors, 85%), but just adding one or two more negative tumors would 'demote' the gene to the ambiguous class by decreasing the frequency below the diagnostic boundary.
On the other hand, genes for which there is evidence for the functionality of mutations, such as BAX (Gil et al., 1999; Ionov et al., 2000) , MSH6 (Baranowskaya et al., 2001), Axin (Liu et al., 2000) or IGFRII (Souza et al., 1999) , do not make the cutoff line for relevancy in some or all of the MSI-positive tumors. Therefore, these studies fall under the old maxim that if observations rely on statistical validation, it would suggest an urgent need to perform a better experiment. Of course, there is the argument that the approach formally forbids the conclusion that genes within the inconclusive area are not functional (the method only establishes that they do not escape the category of doubtful targets). However, this would amount to little more than statistical rhetorical sophistry. Nevertheless, while not perfect, the approach is useful.
Thus, Woerner et al. describe not only how to spot 'true' target genes, but also genes whose mutations may be under negative selection during tumor progression. This is important because it addresses the problematic issue of establishing the relevancy of the absence of an event rather than its presence. It could be viewed as a situation equivalent to the insightful Sherlockian conclusion (in the 'Adventure of Silver Blaze') that the relevant incident was that the dog did not bark in the night (when the racing horse disappeared). For absence of evidence is sometimes evidence of absence. Thus, a couple of genes (CHD2 and RFC3) involved in genome integrity are categorized as being under negative selective pressure in colorectal tumorigenesis because of their low mutation incidence. This is interesting, although some other genes, such as DNA polymerase a, that exhibit a conspicuous absence of mutations are not listed in this category. This is because Pola only has a repeat of eight nucleotides, and the approach by Woerner et al. excludes genes that have repeats shorter than 10 nucleotides from being unambiguously classified as subject to negative selective pressure.
Moreover, two non-coding repeats are listed as being under negative selection, which is somewhat odd. The same kind of oddity would be to include non-coding repeat mutations under positive selection. This could have happened if some of the non-coding repeats reported to display a very high mutation frequency (Zhang et al., 2001) had not been excluded from the meta-analysis, as they were shown to be length polymorphisms rather than somatic mutations (Duval et al., 2002b; Suzuki et al., 2002) . However, it is quite possible that MSI-specific mutations in non-coding sequences may also contribute to the manifestation of the malignant phenotype, for instance if they occur in gene regulatory regions that control levels of expression. It is tempting to predict that the list of such genes with putative roles in tumors with MSI will grow in the future, perhaps to the size of the list of genes with mutations in coding repeats. However, it is not clear whether the deletion of a single nucleotide in a 3' UTR homopolymeric tract of 10 adenines could have a clear impact in gene expression (for instance, by altering the half-life of the messenger RNA) to deserve to be the target of a strong negative selection during tumor progression.
Thus, it appears more plausible that mutations (or lack of mutations) in some repeats are actually found (or not found), not because they are under positive (or negative) selection but because of abnormally high (or low) repeat mutation frequencies. Microsatellites of an identical number of repeat units may exhibit different mutability, regardless of coding capabilities, because of the influence of the surrounding sequences in replication fidelity (Zhang et al., 2001; Duval et al., 2002a, b; Suzuki et al., 2002) . Figure 1 of this editorial complies the data from Woerner et al. (in press ), including genes with repeats of 7, 8, 9 and 10 units, ordered by decreasing mutation frequency. Not all these genes found mutated in cancer of the MMP ought to be relevant for the manifestation of the malignant phenotype by these tumor cells. Especially considering that the genes represented are far from comprising the entire set of genes with repeats in the human genome. In other words, many of these mutations are probably inconsequential. However, the figure also highlights the intrinsic difficulty in deciding the relevancy of mutations based on mutational frequency alone. Where to place the relevancy/irrelevancy cut-off line? No matter which statistical method is used, any such decision would always be tainted by a great deal of arbitrariness.
The mutation incidence of microsatellite sequences in an MMR-deficient background thus can be very high or very low (Figure 1 ). While genes with mutations found with high incidence have already a good lead to merit inclusion into the category of 'relevant', genes with infrequent mutations may not be regarded as irrelevant. This is because these tumors accumulate so many mutations that disruption of cell growth and survival regulation can be accomplished in different tumors by mutations in different genes of the same signaling networks (Suzuki et al., 2002) . This may lead to a lower incidence of any particular gene, relative to tumors without mutator phenotype, where very rare mutations are funneled into a few cancer genes with strong oncogenic potential. The first paradox posed by the low incidence of mutations in APC, K-ras or p53 in tumors of the MMP can be thus rationalized. In Figure 1 Genes with coding repeats.
Commentary conclusion, in this scenario, the relevance of microsatellite-specific mutations in MSI-positive tumors can be proven only when there is supporting evidence for functionality, regardless of mutation incidence.
However, all these complications are in fact minor compared to the more fundamental issue of the allelic status of these mutated target genes. There is no doubt that biallelic mutations in genes with proven roles in cell growth or survival have an impact in cell phenotype, regardless of incidence. However, another paradox of tumors with MSI is that while biallelic mutations in irrelevant (i.e. non-coding) sequences are bountiful (>10 5 , Ionov et al., 1993) , mutations in relevant (i.e. coding) sequences (i.e. those of Figure 1 ) are often monoallelic (see for instance Markowitz et al., 1995; Rampino et al., 1997; Yamamoto et al., 1997 Yamamoto et al., , 2000 . But to delve into this issue would take much more space than allowed in this commentary.
